Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 10/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171650 | 0.93 | TAS1R3 (0.45) | P2RX3P2RX2NR1I2S1PR3S1PR1 | |
| SCHEMBL2171681 | 0.86 | P2RX3 (0.61) | P2RX3P2RX2 | |
| SCHEMBL2171032 | 0.81 | P2RX3 (0.49) | P2RX3P2RX2NR1I2 | |
| SCHEMBL2172000 | 0.80 | S1PR3 (0.40) | P2RX3P2RX2S1PR3S1PR1 | |
| SCHEMBL2173127 | 0.78 | XDH (0.43) | P2RX3P2RX2S1PR3 | |
| SCHEMBL2171259 | 0.78 | P2RX3 (0.55) | P2RX3P2RX2NR1I2 | |
| SCHEMBL2170838 | 0.77 | P2RX3 (0.58) | P2RX3P2RX2 | |
| SCHEMBL2185140 | 0.76 | P2RX3 (0.53) | P2RX3P2RX2 | |
| SCHEMBL2172363 | 0.74 | P2RX3 (0.49) | P2RX3P2RX2NR1I2 | |
| SCHEMBL2171685 | 0.73 | S1PR3 (0.42) | P2RX3P2RX2NR1I2S1PR3S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2346825-A2 | MODULATORS OF P2X3 RECEPTOR ACTIVITY | Evotec AG (DE) | 2011-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | ADORA2B, IL1B, AVPR1B | P2RX3 207/4885P2RX2 240/4885NR1I2 400/4885 |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885NR1I2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.